



NEWS RELEASE

ResMed Life Support Ventilators to Join World's Largest Remote Patient Monitoring Network

5/16/2016

- Cloud connectivity and remote patient monitoring coming to ResMed's Astral™ life support ventilators
- Enables physicians and HMEs to securely view key patient data in the cloud
- Increases ResMed's lead as #1 worldwide in remote patient monitoring

SAN FRANCISCO, May 16, 2016 /PRNewswire/ -- Patients using in-home life support and their clinicians are about to enjoy the latest in home health technology, remote patient monitoring, thanks to the world's first cellular, cloud-connected in-home life support ventilators.

ResMed (NYSE:RMD) announced today at the American Thoracic Society conference its plan to bring cloud connectivity and its remote patient monitoring software, AirView™, to its Astral life support ventilators, thereby increasing its global lead in number of remotely monitored patients. Today ResMed has more than 2.5 million patients monitored through AirView.

Cloud connectivity will enable physicians and home medical equipment providers (HMEs) to access key patient data in the cloud to better manage and improve the outcomes of the thousands of patients who currently rely on Astral life support ventilators at home – all within ResMed's secure, HIPAA-compliant cloud network. Clinicians will have the option of accessing the patient data via AirView or through the ResMed Data Exchange where they may integrate their own electronic medical records systems with AirView.

"Cloud connectivity is a major factor in the future of healthcare," said ResMed President of Healthcare Informatics, Raj Sodhi. "We've seen the great impact that ResMed's AirView has had on patient outcomes and business

efficiencies related to managing sleep apnea and other respiratory conditions.

"This technology will bring the same benefits to those patients who rely on home life support and have other respiratory needs as well. We're also looking to connect Inova Labs' portable oxygen concentrators after acquiring that company earlier this year."

Introduced in 2014, ResMed's Astral life support ventilators offer unparalleled mobility and ease of use for patients suffering from neuromuscular disease, chronic obstructive pulmonary disease (COPD), and other adult and pediatric respiratory disorders. Astral 100 and Astral 150 life support ventilators offer the best battery-to-weight ratio on the market with an eight-hour internal battery, 24-hour battery life capability with external battery connections, and a weight of only 7.1 pounds (3.2 kilograms).

Select customers are currently piloting cloud connectivity on Astral devices; it's expected to be available widely later this year. See all of our award-winning connected care devices at the ATS conference, Booth #1127, May 15-17, 2016.

About ResMed

ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 1 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries. Find more about ResMed at [ResMed.com](https://www.resmed.com), [Facebook](https://www.facebook.com/resmed), [Twitter](https://twitter.com/resmed) and [LinkedIn](https://www.linkedin.com/company/resmed).

For Media:

Jayne Rubenstein

Public Relations Manager

O: 858-836-6798

news@resmed.com

For Investors:

Agnes Lee

Senior Director, Investor Relations

O: 858-836-5971

investorrelations@resmed.com

Logo - <http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/resmed-life-support-ventilators-to-join-worlds-largest-remote-patient-monitoring-network-300268498.html>

SOURCE ResMed Inc.